BIOGEN INC. (BIIB) Form 8-K — Jul 1, 2026
Biogen issued a preliminary estimate regarding its financial results for the second and third quarters of 2026, citing significant expenses related to acquired in-process research and development. The company expects a pre-tax charge of approximately $164 million in the second quarter, which is projected to negatively impact both GAAP and non-GAAP net income per diluted share by about $0.95.
Key figures
- Q2 2026 eps impact
- $0.95
- Q2 2026 iprd expense
- $164 million
- Q3 2026 eps impact range
- $1.75 - $1.95
- Q3 2026 iprd expense range
- $290 million - $320 million
Price after filing
1 day: +3.0%7 days: -4.5%30 days: -0.2%
Close on the filing date to close N calendar days later (from $209.74). Historical, not a forecast.
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.